Nixon Capital LLC Buys Shares of 195,411 Everus (NYSE:ECG)

Nixon Capital LLC bought a new position in shares of Everus (NYSE:ECGFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 195,411 shares of the company’s stock, valued at approximately $12,848,000. Everus comprises 4.2% of Nixon Capital LLC’s holdings, making the stock its 9th largest holding.

Several other institutional investors also recently modified their holdings of ECG. SRS Capital Advisors Inc. acquired a new stake in shares of Everus in the 4th quarter valued at approximately $26,000. Principal Securities Inc. bought a new stake in Everus in the fourth quarter valued at approximately $27,000. HighMark Wealth Management LLC acquired a new stake in Everus in the fourth quarter worth $28,000. Crews Bank & Trust bought a new position in shares of Everus during the fourth quarter worth $29,000. Finally, Mendota Financial Group LLC acquired a new position in shares of Everus in the 4th quarter valued at $36,000.

Everus Trading Up 4.5 %

Everus stock opened at $35.11 on Tuesday. The firm has a 50 day moving average of $46.83. The company has a quick ratio of 1.50, a current ratio of 1.58 and a debt-to-equity ratio of 0.47. Everus has a twelve month low of $31.38 and a twelve month high of $77.93.

Everus (NYSE:ECGGet Free Report) last announced its earnings results on Tuesday, February 11th. The company reported $0.67 earnings per share for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.06). As a group, analysts anticipate that Everus will post 2.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Oppenheimer raised their price objective on Everus from $70.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 7th. Stifel Nicolaus lowered their price target on Everus from $85.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, February 13th.

Get Our Latest Report on ECG

Insider Buying and Selling

In other Everus news, CFO Maximillian J. Marcy bought 1,300 shares of the firm’s stock in a transaction that occurred on Tuesday, February 25th. The stock was acquired at an average price of $38.99 per share, with a total value of $50,687.00. Following the completion of the transaction, the chief financial officer now owns 5,508 shares in the company, valued at approximately $214,756.92. This trade represents a 30.89 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Rocca Michael Della purchased 1,050 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were acquired at an average cost of $47.56 per share, for a total transaction of $49,938.00. Following the completion of the transaction, the director now directly owns 2,027 shares in the company, valued at approximately $96,404.12. This represents a 107.47 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders bought 3,750 shares of company stock worth $153,853.

About Everus

(Free Report)

Everus Construction Group is providing a full spectrum of construction services through its electrical and mechanical and transmission and distribution specialty contracting services principally in United States. Its specialty contracting services are provided to utility, transportation, commercial, industrial, institutional, renewable and other customers.

Recommended Stories

Want to see what other hedge funds are holding ECG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Everus (NYSE:ECGFree Report).

Institutional Ownership by Quarter for Everus (NYSE:ECG)

Receive News & Ratings for Everus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Everus and related companies with MarketBeat.com's FREE daily email newsletter.